670 related articles for article (PubMed ID: 19059004)
1. New horizons in adjuvants for vaccine development.
Reed SG; Bertholet S; Coler RN; Friede M
Trends Immunol; 2009 Jan; 30(1):23-32. PubMed ID: 19059004
[TBL] [Abstract][Full Text] [Related]
2. Adjuvants for malaria vaccines.
Coler RN; Carter D; Friede M; Reed SG
Parasite Immunol; 2009 Sep; 31(9):520-8. PubMed ID: 19691556
[TBL] [Abstract][Full Text] [Related]
3. Vaccine adjuvants: scientific challenges and strategic initiatives.
Harandi AM; Davies G; Olesen OF
Expert Rev Vaccines; 2009 Mar; 8(3):293-8. PubMed ID: 19249971
[TBL] [Abstract][Full Text] [Related]
4. Adjuvants containing natural and synthetic Toll-like receptor 4 ligands.
Ireton GC; Reed SG
Expert Rev Vaccines; 2013 Jul; 12(7):793-807. PubMed ID: 23885824
[TBL] [Abstract][Full Text] [Related]
5. Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens.
Perrie Y; Mohammed AR; Kirby DJ; McNeil SE; Bramwell VW
Int J Pharm; 2008 Dec; 364(2):272-80. PubMed ID: 18555624
[TBL] [Abstract][Full Text] [Related]
6. Smart adjuvants.
Schmidt CS; Morrow WJ; Sheikh NA
Expert Rev Vaccines; 2007 Jun; 6(3):391-400. PubMed ID: 17542754
[TBL] [Abstract][Full Text] [Related]
7. The perfect mix: recent progress in adjuvant research.
Guy B
Nat Rev Microbiol; 2007 Jul; 5(7):505-17. PubMed ID: 17558426
[TBL] [Abstract][Full Text] [Related]
8. Induction and direction of immune responses by vaccine adjuvants.
Schijns VE
Crit Rev Immunol; 2001; 21(1-3):75-85. PubMed ID: 11642615
[TBL] [Abstract][Full Text] [Related]
9. Adjuvanticity of anti-cD40 in vaccine development.
Cairing J; Barr T; Heath AW
Curr Opin Mol Ther; 2005 Feb; 7(1):73-7. PubMed ID: 15732532
[TBL] [Abstract][Full Text] [Related]
10. Current adjuvants and new perspectives in vaccine formulation.
Montomoli E; Piccirella S; Khadang B; Mennitto E; Camerini R; De Rosa A
Expert Rev Vaccines; 2011 Jul; 10(7):1053-61. PubMed ID: 21806399
[TBL] [Abstract][Full Text] [Related]
11. Adjuvants in perspective.
Vogel FR
Dev Biol Stand; 1998; 92():241-8. PubMed ID: 9554280
[TBL] [Abstract][Full Text] [Related]
12. Strategies to link innate and adaptive immunity when designing vaccine adjuvants.
Garlapati S; Facci M; Polewicz M; Strom S; Babiuk LA; Mutwiri G; Hancock RE; Elliott MR; Gerdts V
Vet Immunol Immunopathol; 2009 Mar; 128(1-3):184-91. PubMed ID: 19042032
[TBL] [Abstract][Full Text] [Related]
13. European union regulatory developments for new vaccine adjuvants and delivery systems.
Sesardic D; Dobbelaer R
Vaccine; 2004 Jun; 22(19):2452-6. PubMed ID: 15193409
[TBL] [Abstract][Full Text] [Related]
14. Vaccine adjuvants revisited.
Aguilar JC; RodrÃguez EG
Vaccine; 2007 May; 25(19):3752-62. PubMed ID: 17336431
[TBL] [Abstract][Full Text] [Related]
15. Improving vaccine performance with adjuvants.
Vogel FR
Clin Infect Dis; 2000 Jun; 30 Suppl 3():S266-70. PubMed ID: 10875797
[TBL] [Abstract][Full Text] [Related]
16. New adjuvants for human vaccines.
Mbow ML; De Gregorio E; Valiante NM; Rappuoli R
Curr Opin Immunol; 2010 Jun; 22(3):411-6. PubMed ID: 20466528
[TBL] [Abstract][Full Text] [Related]
17. Survey of human-use adjuvants.
Kenney RT; Edelman R
Expert Rev Vaccines; 2003 Apr; 2(2):167-88. PubMed ID: 12899569
[TBL] [Abstract][Full Text] [Related]
18. The Vaccine Formulation Laboratory: a platform for access to adjuvants.
Collin N; Dubois PM
Vaccine; 2011 Jul; 29 Suppl 1():A37-9. PubMed ID: 21684427
[TBL] [Abstract][Full Text] [Related]
19. Immunology of vaccine adjuvants.
Ribeiro CM; Schijns VE
Methods Mol Biol; 2010; 626():1-14. PubMed ID: 20099117
[TBL] [Abstract][Full Text] [Related]
20. Vaccine adjuvant technology: from mechanistic concepts to practical applications.
Degen WG; Jansen T; Schijns VE
Expert Rev Vaccines; 2003 Apr; 2(2):327-35. PubMed ID: 12899582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
